Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GlaxoSmithKline awarded up to $200 million by U.S. government to develop new antibiotics
GSK & BARDA have agreed to support the development of several antibiotics to fight antibiotic resistance and bioterrorism.
-
BREO™ ELLIPTA™ gains US approval for the treatment of COPD
GSK & THRX announced that the FDA has approved BREO™ ELLIPTA™ as treatment in patients with COPD, including chronic bronchitis/emphysema.
-
GSK enters new commitment with the GAVI Alliance to supply cervical cancer vaccine for girls in the world’s poorest countries
GSK announced a commitment to GAVI Alliance to supply its cervical cancer vaccine to help protect girls in the world's poorest countries.
-
GSK and Save the Children form unique partnership to save the lives of one million children
A new partnership to save the lives of a million of the poorest children in the world has been launched by GSK and Save the Children.
-
GSK gives update on plans to share detailed clinical trial data as part of its commitment to transparency
GSK today announced progress on its commitment to share more detailed data from its clinical trials.
-
Funding boost for GSK’s open innovation research into diseases affecting the developing world
GSK announced a funding of up to £5m from the Wellcome Trust to support discovering and developing new treatments for diseases
-
Regulatory update: Trametinib US PDUFA date extended to 3 September 2013
GSK today announced that the US Prescription Drug User Fee Act (PDUFA) goal date for trametinib.
-
GSK announces regulatory submission for umeclidinium monotherapy in US
GSK announced the submission of a regulatory application in the US for umeclidinium bromide (UMEC), for patients COPD.
-
GlaxoSmithKline and Impax Pharmaceuticals terminate their collaboration on IPX066
GSK & Impax announced that they are terminating their collaboration for the development of IPX066 outside the United States and Taiwan.
-
GSK announces regulatory submission for umeclidinium monotherapy in European Union
GSK announced the submission of a regulatory application to the EU for umeclidinium bromide (UMEC), for patients with COPD.
-
Results announcement for the first quarter 2013
GSK delivers Q1 2013 core EPS of 26.9p and dividend of 18p
-
GSK and Theravance announce regulatory submission for ANORO™ ELLIPTA™ (UMEC/VI) in Japan
GSK & THRX announced the submission of a regulatory application to the JMHLW for the LAMA/LABA medicine, UMEC/VI for patients COPD.
-
GSK statement in response to OFT Statement of Objections
GSK supports fair competition and we very strongly believe that we acted within the law, as the holder of valid patents for paroxetine
-
FDA Advisory Committee recommends approval of BREO(TM) ELLIPTA(TM) for the treatment of COPD
GSK & THRX announced that PADAC voted that the efficacy and safety data evidence to support approval of BREO™ ELLIPTA™
-
GSK announces first four-strain seasonal influenza vaccine granted marketing authorisation in Germany and the UK
GSK has announced the marketing authorisation of its quadrivalent (four-strain) influenza vaccine in Germany and the UK.
-
GlaxoSmithKline announces start of phase III study of Benlysta® (belimumab ) in patients with vasculitis
GSK announced the start of a Phase III study to evaluate Benlysta® (belimumab) in patients with ANCA - a condition involving inflammation
-
Regulatory update: GlaxoSmithKline receives complete response from FDA for candidate pandemic H5N1 adjuvanted influenza vaccine
GSK announced today that it has received a Complete Response letter from the FDA .
-
GSK publishes 2012 Corporate Responsibility report
Report sets out 23 forward-looking commitments to help measure future performance
-
$500,000 Endowment Gift from The GlaxoSmithKline Foundation Expands Program to Help Patients with Cancer and their Families at The Children’s Hospital of Philadelphia
The Children’s Hospital of Philadelphia is proud to announce a $500,000 gift from the GSK Foundation.
-
Young scientists challenged by GSK and McLaren to help drive science behind Formula 1™
GSK and the McLaren Group announce new science education initiative to inspire young people into science and engineering careers